PubMed HealthSearch

PubMed · 8946121

Reducing pain during procedures.

Abstract

There is an increasing focus on the recognition, assessment, and management of pain in children. Children undergo many painful procedures in different clinical environments and are frequently undertreated for their pain. The pediatrician should be familiar with general concepts about the perception of pain in children. Many pain-assessment tools have been developed and restructured to provide the clinician with valid and reliable scales to assess pain in children and assess the effect of interventions. New pharmacologic agents for conscious sedation are being used with increasing frequency in the pediatric outpatient setting for reducing pain and anxiety. Also there has been increasing use of regional anesthetic techniques for procedures once requiring general anesthesia. There has been an increase in the development of topical anesthetics as well as modifying injectable local anesthetic to decrease the pain of local infiltration. Nonpharmacologic methods of pain management are being tested, developed, and used alone or as adjuncts to pharmacologic therapy for children undergoing painful procedures. It is imperative that clinicians keep themselves informed about new advances pertaining to pain treatment and incorporate them into their practices.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E L Liebelt. 1996. Reducing pain during procedures.. https://doi.org/10.1097/00008480-199610000-00003

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.

Conformationally constrained analogues of the potent muscarinic agonist 3-(4-methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methy lpyridine (methylthio-TZTP, 17) were designed and synthesized with the aim of (a) improving the antinociceptive selectivity over salivation and tremor and (b) predicting the active conformation of 17 with respect to the dihedral angle C4-C3-C3'-N2'. Using MOPAC 6.0 tricyclic analogues (7, 15, 16) with C4-C3-C3'-N2' dihedral angles close to 180 degrees and a rotation hindered analogue (9) with a C4-C3-C3'-N2' dihedral angle close to 274 degrees were designed, as these conformations had previously been suggested as being the active conformations. The analogues were tested for central muscarinic receptor binding affinity, for their antinociceptive activity in the mouse grid shock test, and, in the same assay, for their ability to induce tremor and salivation. The data showed that the tricyclic analogues (7, 15, 16) were equipotent with 17 as analgesics, but with no improved side effect profiles. The rotation-hindered analogue 9 had neither muscarinic receptor binding affinity nor antinociceptive activity. These results suggest that the active conformation of 17 has a C3-C4-C3'-N2' dihedral angle close to 180 degrees.

Analgesics

Modulation by serum glucose levels on morphine-induced antinociceptive effect in C57BL/KsJ-db/db mice.

The role of serum glucose levels on the sensitivity to the antinociceptive effect of morphine in streptozotocin-induced diabetic mice and C57BL/KsJ db/db mice were examined. The sensitivity to the antinociceptive effect of morphine was significantly reduced in streptozotocin-induced diabetic mice as compared with age-matched nondiabetic mice. Pretreatment with insulin (3 U/kg, s.c.) significantly reduced the serum glucose levels of streptozotocin-induced diabetic mice as compared with those of untreated diabetic mice. However, post-drug (morphine) tail-flick latency was not affected by pretreatment with insulin. The antinociceptive effect of morphine was also significantly reduced in C57BL/KsJ-db/db mice as compared with age-matched control mice. When CS-045 was administered to C57BL/KsJ-db/db mice, the serum glucose levels were significantly reduced. There was no significant difference in the antinociceptive effect of morphine between CS-045-treated C57BL/KsJ-db/db mice and C57BL/KsJ-db/++ mice. Adoptive transfer of supernatant of the spleen cell homogenate from C57BL/KsJ-db/db mice to naive ICR mice had no significant effect on the recipients' antinociceptive sensitivities to s.c. morphine. These findings support the our previous suggestion that some factor(s) derived from spleen mononuclear cells is the prime factor involving the insulin-insensitive mechanisms for the reduction of mu-opioid agonist-induced antinociception during the severe stages of diabetes.

Analgesics